Amgen Inc.

Tularik Limited

Vigil Neuroscience, Inc.

Japan Tobacco Inc.

Other

Jonathan B Houze

Julio Cesar Medina

Zhihua Ma

Paul John Dransfield

Vatee Pattaropong

Zice Fu

Lawrence R McGee

Su-Jen Lai

Nobuko Nishimura

Julie Anne Heath

Xiaohui Du

David John Kopecky

Mikkel V Debenedetto

Gayathri Swaminath

Xiaoqi Chen

Alan C Cheng

Xiaodong Wang

Richard V Connors

Steven H Olson

Ning Chen

Frank Kayser

Yingcai Wang

Yinhong Chen

Aarif Yusuf Khakoo

Jeffrey Thomas Mihalic

Jiwen Liu

Wen-Chen Yeh

Jeffrey Deignan

Kevin Chao Yang

Matthew R Kaller

Liusheng Zhu

Ted Charles Judd

Rajiv Sharma

Daniel B Horne

Steven Marc Rubenstein

Simon J Hedley

James S Harvey

Michael J Schmitt

Ryan D White

Sean P Brown

Gwenaella Rescourio

Marc Vimolratana

Haoxuan Wang

Jinqian Liu

Vincent Santora

Robert P Farrell

Yongwei Wu

Lara C Czabaniuk

Timothy Hopper

Alice R Wong

Wang Shen

Todd J Kohn

Ming Yu

XianYun Jiao

SuJen Lai

Jane Panteleev

Juan Carlos Jaen

Jian Luo

Zhongyu Wang

Xian Yun Jiao

Hiroyuki Abe

John A Flygare

Bei Shan

Timothy David Cushing

Hisashi Shinkai

Hilary Plake Beck

Jin-Long Chen

Charles Kreiman

An-Rong Li

Patrick C Kearney

Lars V Heumann

Mike Elias Lizarzaburu

Jian Zhang

Sharon McKendry

Atsushi Hagiwara

Matthew Irvine Brown

Xuelei Yan

Michael G Johnson

Leping Li

Yosup Rew

Felix Gonzalez Lopez De Turiso

Xianghong Wang

Mario G Cardozo

Jason A Duquette

Ana Zurisadai Gonzalez Buenrostro

Kexue Li

Feng Xu

Zhihong Li

Alan X Huang

David Louis Clark

Jie Zhang

Yunxiao Li

Michael R Degraffenreid

David C Moebius

YuMei Xiong

Jiasheng Fu

Manuel Zancanella

Joshua Taygerly

Michael W Gribble, Jr

Yongli Su

The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (1).

The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ('TREM2'). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use

The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ('TREM2').  This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Compounds that inhibit MCL-1 protein

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein. 

Alkyl substituted triazole compounds as agonists of the APJ Receptor

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heteroaryl-substituted triazoles as APJ receptor agonists

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I) (II) where the definitions of the variables are provided herein. 

Cycloalkyl substituted triazole compounds as agonists of the APJ receptor

Triazole phenyl compounds as agonists of the APJ receptor

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed. 

Triazole furan compounds as agonists of the APJ receptor

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the structures where the definitions of the variables are provided herein. 

Triazole pyridyl compounds as agonists of the APJ receptor

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Triazole agonists of the APJ receptor

Growing community of inventors

San Mateo, CA, United States of America

Jonathan B Houze